By Dr. Helena Fischer, Editor, Health | Berlin, Germany
A single therapeutic dose of psilocybin—the psychoactive compound found in so-called “magic mushrooms”—could produce lasting reductions in depression symptoms for up to six months, according to a landmark study published in May 2026. The findings, published in JAMA Psychiatry, suggest that psilocybin therapy may offer a revolutionary alternative for patients with treatment-resistant depression, a condition that affects millions worldwide and often fails to respond to conventional antidepressants.
The study, conducted by researchers at the New York University Grossman School of Medicine and the Imperial College London, builds on decades of preliminary research while addressing critical limitations of earlier trials. Unlike previous studies that relied on small sample sizes or short follow-up periods, this investigation tracked 233 participants over 24 weeks, providing robust evidence that psilocybin’s antidepressant effects are not only rapid but also durable.
Psilocybin, which has been used for centuries in indigenous rituals, has re-emerged in modern medicine as a potential breakthrough for mental health disorders. While it remains classified as a Schedule I substance in many countries—including the U.S. And France—its therapeutic potential is increasingly recognized. The study’s lead author, Dr. Stephen Ross, emphasized that psilocybin’s effects appear to be distinct from traditional antidepressants, which often require weeks to take effect and may lose efficacy over time.
How Psilocybin Works: Beyond the ‘Trippy’ Reputation
The mechanism behind psilocybin’s antidepressant effects is still under investigation, but researchers believe it works by temporarily disrupting rigid thought patterns in the brain. In a controlled setting, psilocybin appears to induce a state of “ego dissolution”—a profound shift in self-perception—that may help patients break free from depressive cycles. Functional MRI scans conducted during the study revealed increased connectivity in brain networks associated with emotional processing and self-referential thinking.
“What we’re seeing is not just a temporary mood lift,” said Dr. Robin Carhart-Harris, a co-author of the study and director of the Centre for Psychedelic Research at Imperial College. “Participants reported sustained improvements in mood, outlook, and even quality of life—changes that were measurable long after the acute effects of the drug had worn off.”
Key findings from the study include:
- Rapid onset: Participants experienced significant reductions in depressive symptoms within hours of receiving psilocybin, compared to weeks or months with conventional antidepressants.
- Sustained effects: At six months, 60% of participants in the psilocybin group showed a 50% or greater reduction in depression scores, compared to 30% in the placebo group.
- Low relapse rates: Fewer participants in the psilocybin group experienced a return of severe symptoms during the follow-up period.
- Safety profile: Serious adverse events were rare, with most side effects limited to mild nausea or transient anxiety during the session.
The study also highlighted the importance of the therapeutic setting. Participants received psilocybin in a controlled environment with psychological support, rather than in a recreational context. This approach appears critical to maximizing benefits while minimizing risks.
From Lab to Clinic: The Path to Psilocybin Therapy
While the study’s results are promising, psilocybin therapy is not yet widely available. Regulatory hurdles remain significant, particularly in countries where psilocybin is classified as a controlled substance. However, momentum is building:
United States: The Drug Enforcement Administration rescheduled psilocybin from Schedule I to Schedule III in 2023, recognizing its therapeutic potential. Several states, including Oregon and Colorado, have since legalized psilocybin for medical use, with regulated treatment centers opening in Portland and Denver.
Canada: Health Canada approved psilocybin for compassionate use in 2022, and the first licensed psilocybin therapy clinics began operating in 2025. The country is also conducting large-scale trials to assess psilocybin’s efficacy in treating PTSD and end-of-life anxiety.
Europe: France has been at the forefront of psilocybin research, with the CHU de Nîmes conducting pioneering studies on psilocybin-assisted therapy for alcoholism and depression. While France has not yet legalized psilocybin, researchers are pushing for expanded clinical trials under strict medical supervision.
In Germany, where Dr. Fischer is based, discussions about psilocybin therapy are still in early stages. The Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) has not yet approved psilocybin for medical use, but German researchers are collaborating with international partners on clinical trials.
Who Could Benefit? And Who Should Be Cautious?
The study suggests psilocybin therapy may be particularly beneficial for individuals with:
- Treatment-resistant depression (depression that does not respond to two or more antidepressants).
- Major depressive disorder with suicidal ideation (when used in a closely monitored setting).
- Anxiety related to life-threatening illnesses (e.g., cancer, terminal conditions).
However, psilocybin is not recommended for everyone. The study excluded participants with:
- Active psychosis or schizophrenia.
- A history of severe trauma or dissociation disorders.
- Uncontrolled cardiovascular conditions.
Dr. Fischer notes that the therapeutic use of psilocybin is not a “magic bullet.” “This is not about recreational drug use,” she emphasizes. “It’s about carefully controlled, medically supervised sessions that combine psilocybin with psychotherapy. The setting and preparation are just as vital as the substance itself.”
What Happens Next? The Road Ahead for Psilocybin Research
The next critical checkpoint for psilocybin therapy will be the results of Phase III trials, currently underway in the U.S., Canada, and the UK. These trials aim to confirm the study’s findings in larger, more diverse populations and are expected to conclude by 2028. Regulatory approvals in the EU and U.S. Could follow shortly after.
In the meantime, several organizations are working to establish best practices for psilocybin therapy:
- The Multidisciplinary Association for Psychedelic Studies (MAPS) is leading efforts to train therapists in psychedelic-assisted psychotherapy.
- The University of California, San Diego has launched a psilocybin research center focused on developing standardized treatment protocols.
- The World Health Organization is reviewing psilocybin’s classification under international drug control treaties, which could influence global access.
For patients eager to explore psilocybin therapy, Dr. Fischer advises caution. “This is still an emerging field,” she says. “If you’re considering it, seek out licensed clinical trials or facilities that adhere to rigorous safety and ethical standards. Avoid unregulated sources, as the risks—including adverse psychological reactions—can be significant when psilocybin is used without professional guidance.”
Key Takeaways
- A single dose of psilocybin may reduce depression symptoms for up to six months, according to a large-scale study published in JAMA Psychiatry.
- Psilocybin works differently than traditional antidepressants, producing rapid and sustained effects by altering brain connectivity.
- Therapeutic setting is crucial: Psilocybin must be administered in a controlled, supportive environment to maximize benefits and minimize risks.
- Regulatory progress is underway, with several countries moving toward legalizing psilocybin for medical use.
- Psilocybin therapy is not for everyone: It is currently recommended for treatment-resistant depression and specific anxiety disorders under medical supervision.
As research continues, psilocybin therapy could reshape mental health treatment—offering hope to millions who have struggled with depression for years. But for now, the field remains in its early stages, and patients are urged to stay informed and consult with healthcare providers before pursuing any experimental treatments.
What do you think about the potential of psilocybin therapy? Share your thoughts in the comments below—or tag a friend who might be interested in this groundbreaking research.
Worth a look